Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
12 "Ho Kyung Seo"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Genitourinary cancer
TNM-Based Head-to-Head Comparison of Urachal Carcinoma and Urothelial Bladder Cancer: Stage-Matched Analysis of a Large Multicenter National Cohort
Sang Hun Song, Jaewon Lee, Young Hwii Ko, Jong Wook Kim, Seung Il Jung, Seok Ho Kang, Jinsung Park, Ho Kyung Seo, Hyung Joon Kim, Byong Chang Jeong, Tae-Hwan Kim, Se Young Choi, Jong Kil Nam, Ja Yoon Ku, Kwan Joong Joo, Won Sik Jang, Young Eun Yoon, Seok Joong Yun, Sung-Hoo Hong, Jong Jin Oh
Cancer Res Treat. 2023;55(4):1337-1345.   Published online April 17, 2023
DOI: https://doi.org/10.4143/crt.2023.417
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Outcome analysis of urachal cancer (UraC) is limited due to the scarcity of cases and different staging methods compared to urothelial bladder cancer (UroBC). We attempted to assess survival outcomes of UraC and compare to UroBC after stage-matched analyses.
Materials and Methods
Total 203 UraC patients from a multicenter database and 373 UroBC patients in single institution from 2000 to 2018 were enrolled (median follow-up, 32 months). Sheldon stage conversion to corresponding TNM staging for UraC was conducted for head-to-head comparison to UroBC. Perioperative clinical variables and pathological results were recorded. Stage-matched analyses for survival by stage were conducted.
Results
UraC patients were younger (mean age, 54 vs. 67 years; p < 0.001), with 163 patients (80.3%) receiving partial cystectomy and 23 patients (11.3%) radical cystectomy. UraC was more likely to harbor ≥ pT3a tumors (78.8% vs. 41.8%). While 5-year recurrence-free survival, cancer-specific survival (CSS) and overall survival were comparable between two groups (63.4%, 67%, and 62.1% in UraC and 61.5%, 75.9%, and 67.8% in UroBC, respectively), generally favorable prognosis for UraC in lower stages (pT1-2) but unfavorable outcomes in higher stages (pT4) compared to UroBC was observed, although only 5-year CSS in ≥ pT4 showed statistical significance (p=0.028). Body mass index (hazard ratio [HR], 0.929), diabetes mellitus (HR, 1.921), pathologic T category (HR, 3.846), and lymphovascular invasion (HR, 1.993) were predictors of CSS for all patients.
Conclusion
Despite differing histology, UraC has comparable prognosis to UroBC with relatively favorable outcome in low stages but worse prognosis in higher stages. The presented system may be useful for future grading and risk stratification of UraC.

Citations

Citations to this article as recorded by  
  • Clinical Presentation and Targeted Interventions in Urachal Adenocarcinoma: A Single-Institution Case Series and Review of Emerging Therapies
    Akshay Mathavan, Akash Mathavan, Rodrigo Murillo-Alvarez, Kriti Gera, Urszula Krekora, Aaron J. Winer, Mohit Mathavan, Ellery Altshuler, Brian Hemendra Ramnaraign
    Clinical Genitourinary Cancer.2024; 22(1): 67.     CrossRef
  • Robotic‐assisted approaches to urachal carcinoma: A comprehensive systematic review of the safety and efficacy outcomes
    Caio Vinícius Suartz, Lucas Motta Martinez, Pedro Henrique Brito, Carlos Victori Neto, Maurício Dener Cordeiro, Luiz Antonio Assan Botelho, Fábio Pescarmona Gallucci, José Maurício Mota, William Carlos Nahas, Leopoldo Alves Ribeiro‐Filho
    BJUI Compass.2024; 5(3): 327.     CrossRef
  • 3,461 View
  • 207 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
Identification of Significant Prognostic Tissue Markers Associated with Survival in Upper Urinary Tract Urothelial Carcinoma Patients Treated with Radical Nephroureterectomy: A Retrospective Immunohistochemical Analysis Using Tissue Microarray
Sung Han Kim, Weon Seo Park, Boram Park, Jinsoo Chung, Jae Young Joung, Kang Hyun Lee, Ho Kyung Seo
Cancer Res Treat. 2020;52(1):128-138.   Published online June 19, 2019
DOI: https://doi.org/10.4143/crt.2019.119
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to identify prognostic tissue markers for several survival outcomes after radical nephroureterectomy among patients with upper urinary tract urothelial carcinoma using tissue microarray and immunohistochemistry.
Materials and Methods
Retrospectively, data of 162 non-metastatic patients with upper urinary tract urothelial carcinoma after radical nephroureterectomy between 2004 and 2016 were reviewed to determine intravesical recurrence-free survival (IVRFS), disease-free survival (DFS), and overall survival (OS). The expression of 27 tissue markers on a tissue microarray of radical nephroureterectomy samples and prognostic values of clinicopathological parameters were evaluated using immunohistochemistry and Cox proportional hazard models after adjusting for significant prognostic clinicopathological variables. The expression of all tissue markers was categorized into a binary group with continuous H-scores (0-300).
Results
Median follow-up was 53.4 months (range, 3.6 to 176.5 months); and, 58 (35.8%), 48 (29.6%), and 19 (11.7%) bladder recurrence, disease progression, and all cause death, respectively, were identified. After adjusting for significant clinicopathological factors including intravesical instillation for bladder recurrence-free survival, pathologic T category and intravesical instillation for disease progression-free survival , and pathologic T category for OS (p < 0.05), IVRFS was associated with epithelial cadherin (hazard ratio [HR], 0.49), epidermal growth factor receptor/erythroblastosis oncogene B (c-erb) (HR, 2.59), and retinoblastoma protein loss (HR, 1.85); DFS was associated with cyclin D1 (HR, 2.16) and high-molecular-weight cytokeratin (HR, 0.42); OS was associated with E-cadherin (HR, 0.34) and programmed cell death 1 ligand (HR, 13.42) (p < 0.05).
Conclusion
Several significant tissue markers were associated with survival outcomes in upper urinary tract urothelial carcinoma patients treated with radical nephroureterectomy.

Citations

Citations to this article as recorded by  
  • A multi‐institutional retrospective study of open versus laparoscopic nephroureterectomy focused on the intravesical recurrence
    Soichiro Shimura, Kazumasa Matsumoto, Masaomi Ikeda, Shigenori Moroo, Dai Koguchi, Yoshinori Taoka, Takahiro Hirayama, Yasukiyo Murakami, Takuji Utsunomiya, Daisuke Matsuda, Norihiko Okuno, Akira Irie, Masatsugu Iwamura
    Asia-Pacific Journal of Clinical Oncology.2023; 19(1): 71.     CrossRef
  • Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario
    Giulia Mazzaschi, Giulia Claire Giudice, Matilde Corianò, Davide Campobasso, Fabiana Perrone, Michele Maffezzoli, Irene Testi, Luca Isella, Umberto Maestroni, Sebastiano Buti
    Technology in Cancer Research & Treatment.2023;[Epub]     CrossRef
  • Prognostic value of programmed death ligand‐1 and programmed death‐1 expression in patients with upper tract urothelial carcinoma
    Luca Campedel, Eva Compérat, Géraldine Cancel‐Tassin, Justine Varinot, Christian Pfister, Clara Delcourt, Françoise Gobet, Mathieu Roumiguié, Pierre‐Marie Patard, Gwendoline Daniel, Pierre Bigot, Julie Carrouget, Caroline Eymerit, Stéphane Larré, Priscill
    BJU International.2023; 132(5): 581.     CrossRef
  • The Prevalence and Prognostic Role of PD-L1 in Upper Tract Urothelial Carcinoma Patients Underwent Radical Nephroureterectomy: A Systematic Review and Meta-Analysis
    Yi Lu, Jiaqi Kang, Zhiwen Luo, Yuxuan Song, Jia Tian, Zhongjia Li, Xiao Wang, Li Liu, Yongjiao Yang, Xiaoqiang Liu
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • 7,053 View
  • 141 Download
  • 4 Web of Science
  • 4 Crossref
Close layer
Oncologic, Perioperative Outcomes of Female Radical Cystectomy: Results from a Multicenter Study in Korea
Ji Sung Shim, Ho Kyung Seo, Ja Hyeon Ku, Byong Chang Jeong, Bumsik Hong, Seok Ho Kang, UCART (Urothelial Cancer-Advanced Research and Treatment Group in Korea) Group
Cancer Res Treat. 2019;51(3):1064-1072.   Published online October 30, 2018
DOI: https://doi.org/10.4143/crt.2018.515
AbstractAbstract PDFPubReaderePub
Purpose
The lower incidence of bladder cancer among women has led to a lack of information on female radical cystectomy (RC). This study aimed to analyze the characteristics related with female RC in a cohort from multiple academic institutions.
Materials and Methods
This was a retrospective review of 384 female patients who underwent RC for bladder cancer. Epidemiologic, perioperative variables including urologic referral periodwith consequent pathologic stage distributions were assessed. The changes in surgical techniques over time were illustrated. Also, we evaluated recurrence-free survival (RFS) at 2 and 5 years and overall survival (OS) at 5 years with stage-specific analyses using the Kaplan-Meier method.
Results
The mean follow-up time was 35 months (interquartile rage [IQR], 9 to 55). The average time to urologic referral with initial symptoms was 5.5 (IQR, 1 to 6) months and over 20% of patients visited clinics after 6 months. In subsequent stage distributions according to referral period, T2 or higher stage distributions were abruptly increased after 1 year. Overall 2-year/5-year RFS rates were 0.72/0.57 and 5-year OS was 0.61. Notable surgical descriptions were as follows: 91% of patients underwent open RC; 80% of patients underwent an ileal conduit; and 83% of patients received anterior exenteration. However, the proportions of robotic surgery, orthotopic neobladder and organ sparing cystectomy have increased recen-tly.
Conclusion
We identified the general characteristics and changes in pattern of female RC. Our results also suggest that women are susceptible to delays in referral to an urologist and are at greater risk for worse prognosis.

Citations

Citations to this article as recorded by  
  • Perioperative, oncological, and survival outcomes of robotic radical cystectomy with urinary diversion in females
    Varun V. Agarwal, B. Yuvaraja Thyavihally, Santosh Subhash Waigankar, Preetham Dev, Abhinav P. Pednekar, Diptiman Roy, Nevitha Athikari, Meenal Hastak, Naresh Badlani, D. Harshwardhan Pokharkar, Nagaraja Sekhar Ayyalasomayajula, Archan Khandekar, Ashish A
    Indian Journal of Urology.2023; 39(1): 27.     CrossRef
  • Safety and Efficacy of Reproductive Organ-Sparing Radical Cystectomy in Women With Variant Histology and Advanced Stage
    Sunil H. Patel, Shirley Wang, Meredith R. Metcalf, Natasha Gupta, Andrew Gabrielson, Esther Lee, Mary Rostom, Phil Pierorazio, Armine Smith, Noah Hahn, Mark Schoenberg, Max Kates, Jean Hoffman-Censits, Trinity J. Bivalacqua
    Clinical Genitourinary Cancer.2022; 20(1): 60.     CrossRef
  • The learning curve for robot-assisted radical cystectomy with total intracorporeal urinary diversion based on radical cystectomy pentafecta
    Tae Il Noh, Ji Sung Shim, Sung Gu Kang, Jun Cheon, Jong Hyun Pyun, Seok Ho Kang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • 6,864 View
  • 144 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
Laparoscopy versus Open Nephroureterectomy in Prognostic Outcome of Patients with Advanced Upper Tract Urothelial Cancer: A Retrospective, Multicenter, Propensity-Score Matching Analysis
Sung Han Kim, Mi Kyung Song, Jung Kwon Kim, Bumsik Hong, Seok Ho Kang, Ja Hyeon Ku, Byong Chang Jeong, Ho Kyung Seo, On behalf of Urothelial Cancer-Advanced Research and Treatment (UCART) Study Group
Cancer Res Treat. 2019;51(3):963-972.   Published online October 12, 2018
DOI: https://doi.org/10.4143/crt.2018.465
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to compare oncologic outcomes between open nephroureterectomy (ONU) and laparoscopic nephroureterectomy (LNU) in patients with upper tract urothelial carcinoma.
Materials and Methods
The medical records of consecutive ONU and LNU cases from five tertiary institutions were retrospectively analyzed between 2000 and 2012. The propensity-score matching methodology was used to compare the two surgical approaches in terms of age, body mass index, American Society of Anesthesiologists score, tumor location, grade, pathologic T and N categories, the presence of lymphovascular invasion, and follow-up duration. The Kaplan-Meier with log-rank tests and clustered Cox regression were used to compare the estimated rates of survival for each surgical approach and to investigate the effect of the surgical approach on each prognostic outcome.
Results
Six hundred thirty-eight propensity-score matching pairs (n=1,276) were compared; LNU was significantly better than ONU in all types of survival, including intravesical recurrencefree survival (IVRFS), disease-free survival, overall survival (OS), and cancer-specific survival (CSS) (p < 0.05). The 3-year OS and CSS rates were significantly higher with LNU than with ONU (p < 0.05). Compared with ONU, LNU had significantly better 3-year OS and CSS rates (82.9% and 86.2% vs. 78.3% and 81.8%); there were no differences at 5 years. In subgroup analysis of the early-staged group, advanced-stage group, lymph node–positive group, and lymph node–negative group, the two approaches did not significantly affect prognostic outcomes, except LNU improved the IVRFS in the lymph node–negative or no history of previous bladder cancer group.
Conclusion
LNU had a significantly better prognostic outcome than ONU after propensity-score matching.

Citations

Citations to this article as recorded by  
  • Laparoscopic Versus Open Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-Analysis of Propensity-Score Matched Studies
    Shidong Deng, Lingzhi Liu, Yurou Wang, Chuan Zhou, Huihui Zhang
    Surgical Innovation.2024; 31(5): 520.     CrossRef
  • Differential effect of surgical technique on intravesical recurrence after radical nephroureterectomy in patients with upper tract urothelial cancer: a systematic review and Meta-analysis
    Ichiro Tsuboi, Akihiro Matsukawa, Mehdi Kardoust Parizi, Jakob Klemm, Robert J Schulz, Anna Cadenar, Stefano Mancon, Sever Chiujdea, Tamás Fazekas, Marcin Miszczyk, Ekaterina Laukhtina, Tatsushi Kawada, Satoshi Katayama, Takehiro Iwata, Kensuke Bekku, Koi
    World Journal of Urology.2024;[Epub]     CrossRef
  • Comparing Oncological and Perioperative Outcomes of Open versus Laparoscopic versus Robotic Radical Nephroureterectomy for the Treatment of Upper Tract Urothelial Carcinoma: A Multicenter, Multinational, Propensity Score-Matched Analysis
    Nico C. Grossmann, Francesco Soria, Tristan Juvet, Aaron M. Potretzke, Hooman Djaladat, Alireza Ghoreifi, Eiji Kikuchi, Andrea Mari, Zine-Eddine Khene, Kazutoshi Fujita, Jay D. Raman, Alberto Breda, Matteo Fontana, John P. Sfakianos, John L. Pfail, Ekater
    Cancers.2023; 15(5): 1409.     CrossRef
  • Factors Predicting Oncological Outcomes of Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma in Taiwan
    I-Hsuan Alan Chen, Chao-Hsiang Chang, Chi-Ping Huang, Wen-Jeng Wu, Ching-Chia Li, Chung-Hsin Chen, Chao-Yuan Huang, Chi-Wen Lo, Chih-Chin Yu, Chung-You Tsai, Wei-Che Wu, Jen-Shu Tseng, Wun-Rong Lin, Yuan-Hong Jiang, Yu-Khun Lee, Yeong-Chin Jou, Ian-Seng C
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Robotic Radical Nephroureterectomy with Bladder Cuff Excision for Upper Tract Urothelial Carcinoma: A Trend Analysis of Utilization and a Comparative Study
    Hoyoung Bae, Jae Hoon Chung, Wan Song, Minyong Kang, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Hyun Hwan Sung
    Cancers.2022; 14(10): 2497.     CrossRef
  • Oncological outcomes of laparoscopic versus open nephroureterectomy for the treatment of upper tract urothelial carcinoma: an updated meta-analysis
    Radosław Piszczek, Łukasz Nowak, Wojciech Krajewski, Joanna Chorbińska, Sławomir Poletajew, Marco Moschini, Krzysztof Kaliszewski, Romuald Zdrojowy
    World Journal of Surgical Oncology.2021;[Epub]     CrossRef
  • Laparoscopic compared with open nephroureterectomy in upper urinary tract urothelial carcinoma: A systemic review and a meta‐analysis
    Guihong Liu, Zeqin Yao, Guoqiang Chen, Yalang Li, Bing Liang
    International Journal of Clinical Practice.2021;[Epub]     CrossRef
  • RETRACTED: Open Nephroureterectomy Compared to Laparoscopic in Upper Urinary Tract Urothelial Carcinoma: A Meta-Analysis
    Guihong Liu, Zeqin Yao, Guoqiang Chen, Yalang Li, Bing Liang
    Frontiers in Surgery.2021;[Epub]     CrossRef
  • A retrospective multicenter comparison of conditional cancer-specific survival between laparoscopic and open radical nephroureterectomy in locally advanced upper tract urothelial carcinoma
    Sung Han Kim, Mi Kyung Song, Ja Hyeon Ku, Seok Ho Kang, Byong Chang Jeong, Bumsik Hong, Ho Kyung Seo, Isaac Yi Kim
    PLOS ONE.2021; 16(10): e0255965.     CrossRef
  • Risk factor analysis of intravesical recurrence after retroperitoneoscopic nephroureterectomy for upper tract urothelial carcinoma
    Masato Yanagi, Tsutomu Hamasaki, Jun Akatsuka, Yuki Endo, Hayato Takeda, Yukihiro Kondo
    BMC Urology.2021;[Epub]     CrossRef
  • Diagnosis, management, and follow-up of upper tract urothelial carcinoma: an interdisciplinary collaboration between urology and radiology
    Jacob L. Roberts, Fady Ghali, Lejla Aganovic, Seth Bechis, Kelly Healy, Gerant Rivera-Sanfeliz, Riccardo Autorino, Ithaar Derweesh
    Abdominal Radiology.2019; 44(12): 3893.     CrossRef
  • Prognostic Value of Lymphovascular Invasion in Upper Urinary Tract Urothelial Carcinoma after Radical Nephroureterectomy: A Systematic Review and Meta-Analysis
    Wen Liu, Lijiang Sun, Fengju Guan, Fangming Wang, Guiming Zhang
    Disease Markers.2019; 2019: 1.     CrossRef
  • 7,595 View
  • 174 Download
  • 12 Web of Science
  • 12 Crossref
Close layer
Retrospective Study of the Significant Predictive Role of Inflammatory Degree in Initial and Repeat Prostate Biopsy Specimens for Detecting Prostate Cancer
Sung Han Kim, Boram Park, Jae Young Joung, Jinsoo Chung, Ho Kyung Seo, Kang Hyun Lee, Weon Seo Park
Cancer Res Treat. 2019;51(3):910-918.   Published online October 2, 2018
DOI: https://doi.org/10.4143/crt.2018.314
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to determine whether histologic inflammation (HI) in initial and repeat prostate biopsy specimens was significantly associated with the detection of prostate cancer.
Materials and Methods
Between 2005 and 2017, the clinicopathological records of patients with high prostatespecific antigen (PSA) levels who underwent initial and repeat prostate biopsies were retrospectively reviewed. The presence of HI and its degree in each biopsied specimen were interpreted by one uropathologist with 20 years of experience. The association between HI and cancer diagnosis was statistically assessed, with p < 0.05 considered significant, and the cancer and non-cancer groups were compared.
Results
Among the 522 patients with a median PSA levels of 6.5 ng/dL, including 258 (49.4%) whose cancer was diagnosed following repeat biopsy, the median degrees of HI in the initial and repeat biopsies were 25.0% and 41.7%, respectively. Furthermore, 211 (40.4%) and 247 (47.3%) patients had HI (> 0%) on biopsied specimens, respectively. Comparison of the cancer and noncancer groups revealed that a greater rate of HI specimens in the initial biopsy was associated with fewer prostate cancer diagnoses following repeat biopsy (p < 0.001). Other comparisons between the cancer and non-cancer groups showed that the cancer group had a significantly higher rate of hypertension, whereas those non-cancer group had a significantly higher rate of benign prostatic hyperplasia and prostatitis (p < 0.05).
Conclusion
A finding of a lesser degree of HI in the initial and a greater degree of HI in the repeat biopsied specimens was associated with the higher probability of cancer diagnosis in patients with high PSA levels.

Citations

Citations to this article as recorded by  
  • Growth and differentiation factor 15 and NF‐κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection
    Benjamin A. Rybicki, Sudha M. Sadasivan, Yalei Chen, Oleksandr Kravtsov, Watchareepohn Palangmonthip, Kanika Arora, Nilesh S. Gupta, Sean Williamson, Kevin Bobbitt, Dhananjay A. Chitale, Deliang Tang, Andrew G. Rundle, Kenneth A. Iczkowski
    Cancer Medicine.2021; 10(9): 3013.     CrossRef
  • 6,137 View
  • 144 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
The Comparison of Oncologic Outcomes between Open and Laparoscopic Radical Nephroureterectomy for the Treatment of Upper Tract Urothelial Carcinoma: A Korean Multicenter Collaborative Study
Tae Heon Kim, Bumsik Hong, Ho Kyung Seo, Seok Ho Kang, Ja Hyeon Ku, Byong Chang Jeong, on behalf of Urothelial Cancer-Advanced Research and Treatment (UCART) Study Group
Cancer Res Treat. 2019;51(1):240-251.   Published online April 24, 2018
DOI: https://doi.org/10.4143/crt.2017.417
AbstractAbstract PDFPubReaderePub
Purpose
We compared oncologic outcomes of patients with upper tract urothelial carcinoma (UTUC) who underwent open nephroureterectomy (ONU) or laparoscopic nephroureterectomy (LNU).
Materials and Methods
Consecutive cases of ONU and LNU between 2000 and 2012 at five participating institutions were included in this retrospective analysis. Clinical characteristics and pathologic outcomes were compared between the two surgical approaches. The influence of the type of surgical approach on intravesical recurrence-free survival (IVRFS), progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS) was analyzed using the Kaplan-Meier method and differences were assessed with the log-rank test. Predictors of IVRFS, PFS, CSS, and OS were also analyzed with a multivariable Cox regression model.
Results
A total of 1,521 patients with UTUC were eligible for the present study (ONU, 906; LNU, 615). The estimated 5-year IVRFS (57.8 vs. 51.0%, p=0.010), CSS (80.4 vs. 76.4%, p=0.032), and OS (75.8 vs. 71.4%, p=0.026) rates were significantly different between the two groups in favor of LNU. Moreover, in patients with locally advanced disease (pT3/pT4), the LNU group showed better 5-year IVRFS (62.9 vs. 54.1%, p=0.038), CSS (64.3 vs. 56.9%, p=0.022), and OS (60.4 vs. 53.1%, p=0.018) rates than the ONU group. Multivariable Cox regression analyses showed that type of surgical approach was independently associated with IVRFS, but was not related to PFS, CSS, and OS.
Conclusion
Our findings indicate that LNU provided better oncologic control of IVRFS, CSS, and OS compared with ONU for the management of patients with UTUC.

Citations

Citations to this article as recorded by  
  • Impact of lymphovascular invasion on survival in surgically treated upper tract urothelial carcinoma: a nationwide analysis
    Giuseppe Ottone Cirulli, Nicholas Corsi, Ivan Rakic, Alex Stephens, Giuseppe Chiarelli, Marco Finati, Matthew Davis, Shane Tinsley, Akshay Sood, Nicolò Buffi, Giovanni Lughezzani, Giuseppe Carrieri, Andrea Salonia, Alberto Briganti, Francesco Montorsi, Cr
    BJU International.2024; 133(5): 555.     CrossRef
  • Robotic Radical Nephroureterectomy with Bladder Cuff Excision for Upper Tract Urothelial Carcinoma: A Trend Analysis of Utilization and a Comparative Study
    Hoyoung Bae, Jae Hoon Chung, Wan Song, Minyong Kang, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Hyun Hwan Sung
    Cancers.2022; 14(10): 2497.     CrossRef
  • Impact of pathological factors on survival in patients with upper tract urothelial carcinoma: a systematic review and meta-analysis
    Gopal Sharma, Anuj Kumar Yadav, Tarun Pareek, Pawan Kaundal, Shantanu Tyagi, Sudheer Kumar Devana, Shrawan Kumar Singh
    International braz j urol.2022; 48(3): 406.     CrossRef
  • Laparoscopic compared with open nephroureterectomy in upper urinary tract urothelial carcinoma: A systemic review and a meta‐analysis
    Guihong Liu, Zeqin Yao, Guoqiang Chen, Yalang Li, Bing Liang
    International Journal of Clinical Practice.2021;[Epub]     CrossRef
  • RETRACTED: Open Nephroureterectomy Compared to Laparoscopic in Upper Urinary Tract Urothelial Carcinoma: A Meta-Analysis
    Guihong Liu, Zeqin Yao, Guoqiang Chen, Yalang Li, Bing Liang
    Frontiers in Surgery.2021;[Epub]     CrossRef
  • A retrospective multicenter comparison of conditional cancer-specific survival between laparoscopic and open radical nephroureterectomy in locally advanced upper tract urothelial carcinoma
    Sung Han Kim, Mi Kyung Song, Ja Hyeon Ku, Seok Ho Kang, Byong Chang Jeong, Bumsik Hong, Ho Kyung Seo, Isaac Yi Kim
    PLOS ONE.2021; 16(10): e0255965.     CrossRef
  • Unusual presentation of upper urinary tract urothelial carcinoma in Taiwan: Direct comparison from Taiwan‐Japan UTUC Collaboration Cohort
    Hao Lun Luo, Chikara Ohyama, Shingo Hatakeyama, Hung Jen Wang, Tohru Yoneyama, Wen Chou Yang, Yao Chi Chuang, Yen Ta Chen, Wei Chin Lee, Yuan Tso Cheng, Chih Hsiung Kang, Po Hui Chiang
    International Journal of Urology.2020; 27(4): 327.     CrossRef
  • Concomitant carcinoma in situ as a prognostic factor in the upper tract urothelial carcinoma after radical nephroureterectomy: A systematic review and meta-analysis
    Xiaoshuai Gao, Yucheng Ma, Guo Chen, Jixiang Chen, Hao Li, Hong Li, Xin Wei, Kunjie Wang
    Urologic Oncology: Seminars and Original Investigations.2020; 38(6): 574.     CrossRef
  • Transperitoneal radical nephroureterectomy is associated with worse disease progression than retroperitoneal radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma
    Tae Heon Kim, Yoon Seok Suh, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi, Hyun Hwan Sung
    Scientific Reports.2019;[Epub]     CrossRef
  • Diagnosis, management, and follow-up of upper tract urothelial carcinoma: an interdisciplinary collaboration between urology and radiology
    Jacob L. Roberts, Fady Ghali, Lejla Aganovic, Seth Bechis, Kelly Healy, Gerant Rivera-Sanfeliz, Riccardo Autorino, Ithaar Derweesh
    Abdominal Radiology.2019; 44(12): 3893.     CrossRef
  • Prognostic Value of Lymphovascular Invasion in Upper Urinary Tract Urothelial Carcinoma after Radical Nephroureterectomy: A Systematic Review and Meta-Analysis
    Wen Liu, Lijiang Sun, Fengju Guan, Fangming Wang, Guiming Zhang
    Disease Markers.2019; 2019: 1.     CrossRef
  • 8,476 View
  • 212 Download
  • 13 Web of Science
  • 11 Crossref
Close layer
Lifestyle Risk Prediction Model for Prostate Cancer in a Korean Population
Sung Han Kim, Sohee Kim, Jae Young Joung, Whi-An Kwon, Ho Kyung Seo, Jinsoo Chung, Byung-Ho Nam, Kang Hyun Lee
Cancer Res Treat. 2018;50(4):1194-1202.   Published online December 21, 2017
DOI: https://doi.org/10.4143/crt.2017.484
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The use of prostate-specific antigen as a biomarker for prostate cancer (PC) has been controversial and is, therefore, not used by many countries in their national health screening programs. The biological characteristics of PC in East Asians including Koreans and Japanese are different from those in the Western populations. Potential lifestyle risk factors for PC were evaluated with the aim of developing a risk prediction model.
Materials and Methods
A total of 1,179,172 Korean men who were cancer free from 1996 to 1997, had taken a physical examination, and completed a lifestyle questionnaire, were enrolled in our study to predict their risk for PC for the next eight years, using the Cox proportional hazards model. The model’s performance was evaluated using the C-statistic and Hosmer‒Lemeshow type chi-square statistics.
Results
The risk prediction model studied age, height, body mass index, glucose levels, family history of cancer, the frequency of meat consumption, alcohol consumption, smoking status, and physical activity, which were all significant risk factors in a univariate analysis. The model performed very well (C statistic, 0.887; 95% confidence interval, 0.879 to 0.895) and estimated an elevated PC risk in patients who did not consume alcohol or smoke, compared to heavy alcohol consumers (hazard ratio [HR], 0.78) and current smokers (HR, 0.73) (p < 0.001).
Conclusion
This model can be used for identifying Korean and other East Asian men who are at a high risk for developing PC, as well as for cancer screening and developing preventive health strategies.

Citations

Citations to this article as recorded by  
  • To Drink or Not to Drink? Investigating Alcohol’s Impact on Prostate Cancer Risk
    Aris Kaltsas, Michael Chrisofos, Evangelos N. Symeonidis, Athanasios Zachariou, Marios Stavropoulos, Zisis Kratiras, Ilias Giannakodimos, Asterios Symeonidis, Fotios Dimitriadis, Nikolaos Sofikitis
    Cancers.2024; 16(20): 3453.     CrossRef
  • Machine learning algorithms that predict the risk of prostate cancer based on metabolic syndrome and sociodemographic characteristics: a prospective cohort study
    Tao Thi Tran, Jeonghee Lee, Junetae Kim, Sun-Young Kim, Hyunsoon Cho, Jeongseon Kim
    BMC Public Health.2024;[Epub]     CrossRef
  • Combinations of lifestyle behaviors and cancer risk among Korean adults
    Ngoc Minh Luu, Thi Tra Bui, Thi Phuong Thao Tran, Thi Huyen Trang Nguyen, Jin-Kyoung Oh
    Scientific Reports.2023;[Epub]     CrossRef
  • Cigarette smoking and prostate cancer: A systematic review and meta-analysis of prospective cohort studies
    Sarah Al-Fayez, Ashraf El-Metwally
    Tobacco Induced Diseases.2023; 21(February): 1.     CrossRef
  • Prostate cancer risk prediction based on clinical factors and prostate-specific antigen
    Taewon Hwang, Hyungseok Oh, Jung Ah Lee, Eo Jin Kim
    BMC Urology.2023;[Epub]     CrossRef
  • Association Between Red and Processed Meat Consumption and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis
    Saeedeh Nouri-Majd, Asma Salari-Moghaddam, Azadeh Aminianfar, Bagher Larijani, Ahmad Esmaillzadeh
    Frontiers in Nutrition.2022;[Epub]     CrossRef
  • Alcohol and Prostate Cancer: Time to Draw Conclusions
    Amanda J. Macke, Armen Petrosyan
    Biomolecules.2022; 12(3): 375.     CrossRef
  • Diagnostic accuracy of prostate-specific antigen below 4 ng/mL as a cutoff for diagnosing prostate cancer in a hospital setting: A systematic review and meta-analysis
    Yan Jin, Jae Hung Jung, Woong Kyu Han, Eu Chang Hwang, Yoonmi Nho, Narae Lee, Ji Eun Yun, Kwang Suk Lee, Sang Hyub Lee, Hakmin Lee, Su-Yeon Yu
    Investigative and Clinical Urology.2022; 63(3): 251.     CrossRef
  • Association between Relative Preference for Vegetables and Meat and Cancer Incidence in Korean Adults: A Nationwide Population-based Retrospective Cohort Study
    Ga-Eun Yie, An Na Kim, Hyun Jeong Cho, Minji Kang, Sungji Moon, Inah Kim, Kwang-Pil Ko, Jung Eun Lee, Sue K. Park
    Korean Journal of Community Nutrition.2021; 26(3): 211.     CrossRef
  • Prostate Cancer Risk Calculators for Healthy Populations: Systematic Review
    Antonio Bandala-Jacques, Kevin Daniel Castellanos Esquivel, Fernanda Pérez-Hurtado, Cristobal Hernández-Silva, Nancy Reynoso-Noverón
    JMIR Cancer.2021; 7(3): e30430.     CrossRef
  • Personalized 5-Year Prostate Cancer Risk Prediction Model in Korea Based on Nationwide Representative Data
    Yohwan Yeo, Dong Wook Shin, Jungkwon Lee, Kyungdo Han, Sang Hyun Park, Keun Hye Jeon, Jungeun Shin, Aesun Shin, Jinsung Park
    Journal of Personalized Medicine.2021; 12(1): 2.     CrossRef
  • Lifestyles, health habits, and prostate cancer
    Tomoyuki Kawada
    Journal of Cancer Research and Clinical Oncology.2020; 146(6): 1623.     CrossRef
  • Combination possibility and deep learning model as clinical decision-aided approach for prostate cancer
    Okyaz Eminaga, Omran Al-Hamad, Martin Boegemann, Bernhard Breil, Axel Semjonow
    Health Informatics Journal.2020; 26(2): 945.     CrossRef
  • Tailored Biofunctionalized Biosensor for the Label-Free Sensing of Prostate-Specific Antigen
    Sachin Mishra, Eun-Seong Kim, Parshant Kumar Sharma, Zhi-Ji Wang, Sung-Hyun Yang, Ajeet Kumar Kaushik, Cong Wang, Yang Li, Nam-Young Kim
    ACS Applied Bio Materials.2020; 3(11): 7821.     CrossRef
  • A Study on Risk Factors of the Incidence of Prostate Cancer Using National Health Insurance Service: Effects of BMI on Age
    Hye Sim Kim, Tae Hwa Go, Dae Ryong Kang, Jae Hung Jung, Sung Won Kwon, Sae Chul Kim, Jae Mann Song, Hyun Chul Chung, Sang Baek Koh
    Journal of Health Informatics and Statistics.2019; 44(4): 410.     CrossRef
  • 10,092 View
  • 258 Download
  • 13 Web of Science
  • 15 Crossref
Close layer
Second Primary Cancer Risk among Kidney Cancer Patients in Korea: A Population-Based Cohort Study
Jae Young Joung, Whi-An Kwon, Jiwon Lim, Chang-Mo Oh, Kyu-Won Jung, Sung Han Kim, Ho Kyung Seo, Weon Seo Park, Jinsoo Chung, Kang Hyun Lee, Young-Joo Won
Cancer Res Treat. 2018;50(1):293-301.   Published online April 19, 2017
DOI: https://doi.org/10.4143/crt.2016.543
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Secondary primary cancers (SPCs) commonly arise in patients with renal cell carcinoma (RCC). We designed the present study to estimate the SPC incidence in Korean patients with RCC.
Materials and Methods
The study cohort was population-based and consisted of 40,347 individuals from the Korean Central Cancer Registry who were diagnosed with primary renal cancer between 1993 and 2013. Standardized incidence ratios (SIRs) for SPCs were estimated for different ages at diagnosis, latencies, diagnostic periods, and treatments.
Results
For patients with primary RCC, the risk of developing a SPC was higher than the risk of developing cancer in the general population (SIR, 1.13; 95% confidence interval, 1.08 to 1.18). Most cancer types showed higher incidences in patients with RCC than in the general population. However, the relative incidence of gastric cancer as an SPC varied by age. Gastric cancer incidence was elevated in young patients (< 30 years) with RCC, but reduced in older (≥ 30) patients with RCC. Patients with advanced RCC died prematurely, regardless of SPC development. In contrast, those with early-stage RCC survived for longer periods, although SPC development affected their post-RCC survival. After SPC development, women had better survival than men.
Conclusion
In Korean patients with primary RCC, the incidence of SPC was 13% higher than the incidence of cancer in the general population. These findings may play important roles in the conduct of follow-up evaluations and education for patients with RCC.

Citations

Citations to this article as recorded by  
  • Next-generation sequencing identifies the mutational signature of double primary and metastatic malignancies: A case report
    Shiying Tang, Yixiao Deng, Yinan Yan, Jie Bai, Huiying He, Shudong Zhang, Jie Yang, Min Qiu, Xiaojun Tian
    Current Urology.2024;[Epub]     CrossRef
  • Renal cell carcinoma and risk of second primary cancer: A Danish nationwide cohort study
    Maria B. Bengtsen, Dóra K. Farkas, Henrik T. Sørensen, Mette Nørgaard
    Cancer Medicine.2024;[Epub]     CrossRef
  • Chance, ignorance, and the paradoxes of cancer: Richard Peto on developing preventative strategies under uncertainty
    George Davey Smith, Albert Hofman, Paul Brennan
    European Journal of Epidemiology.2023; 38(12): 1227.     CrossRef
  • Better Prognosis and Survival in Esophageal Cancer Survivors After Comorbid Second Primary Malignancies: A SEER Database-Based Study
    Jiayue Ye, Sheng Hu, Wenxiong Zhang, Deyuan Zhang, Yang Zhang, Dongliang Yu, Jinhua Peng, Jianjun Xu, Yiping Wei
    Frontiers in Surgery.2022;[Epub]     CrossRef
  • Effect of prior thyroid cancer on survival of primary liver cancer: a study based on the SEER database
    Hong Liu, Xin Heng, Yuan Tian, Zhongming Yang
    Scientific Reports.2022;[Epub]     CrossRef
  • Being Precise About Precision Mental Health
    Peter Szatmari, Ezra Susser
    JAMA Psychiatry.2022; 79(12): 1149.     CrossRef
  • Second Primary Cancers After Kidney Cancers, and Kidney Cancers as Second Primary Cancers
    Guoqiao Zheng, Kristina Sundquist, Jan Sundquist, Tianhui Chen, Asta Försti, Otto Hemminki, Kari Hemminki
    European Urology Open Science.2021; 24: 52.     CrossRef
  • miR‐34a in extracellular vesicles from bone marrow mesenchymal stem cells reduces rheumatoid arthritis inflammation via the cyclin I/ATM/ATR/p53 axis
    Huaiguo Wu, Xike Zhou, Xuedong Wang, Wei Cheng, Xinjia Hu, Yueping Wang, Bing Luo, Wenjun Huang, Juan Gu
    Journal of Cellular and Molecular Medicine.2021; 25(4): 1896.     CrossRef
  • Deciphering the Risk of Developing Second Primary Thyroid Cancer Following a Primary Malignancy—Who Is at the Greatest Risk?
    Lily N. Trinh, Andrew R. Crawford, Mohammad H. Hussein, Mourad Zerfaoui, Eman A. Toraih, Gregory W. Randolph, Emad Kandil
    Cancers.2021; 13(6): 1402.     CrossRef
  • Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients
    Lucie Pehalova, Denisa Krejci, Jana Halamkova, Lenka Smardova, Lenka Snajdrova, Ladislav Dusek
    Cancer Epidemiology.2021; 72: 101929.     CrossRef
  • Prognosis of patients with axillary lymph node metastases from occult breast cancer: analysis of multicenter data
    Haeyoung Kim, Won Park, Su SSan Kim, Sung Ja Ahn, Yong Bae Kim, Tae Hyun Kim, Jin Hee Kim, Jin-Hwa Choi, Hae Jin Park, Jee Suk Chang, Doo Ho Choi
    Radiation Oncology Journal.2021; 39(2): 107.     CrossRef
  • The Risk and Prognosis of Secondary Primary Malignancy in Lung Cancer: A Population-Based Study
    Jia Hong, Rongrong Wei, Chuang Nie, Anastasiia Leonteva, Xu Han, Xinyu Du, Jing Wang, Lin Zhu, Wenjing Tian, Haibo Zhou
    Future Oncology.2021; 17(33): 4497.     CrossRef
  • Clear Cell Papillary Renal Cell Carcinoma Shares Distinct Molecular Characteristics and may be Significantly Associated With Higher Risk of Developing Second Primary Malignancy
    Xi Tian, Wen-Hao Xu, Jun-Long Wu, Hua-Lei Gan, Hong-Kai Wang, Wei-Jie Gu, Yuan-Yuan Qu, Hai-Liang Zhang, Ding-Wei Ye
    Pathology and Oncology Research.2021;[Epub]     CrossRef
  • Primary Adenocarcinoma of Lung with Synchronous Renal Cell Carcinoma: A Case Report and Review of the Literature
    Sharareh Seifi, Zahra Esfahani-Monfared, Mihan Pourabdollah, Sara Haseli
    International Journal of Cancer Management.2020;[Epub]     CrossRef
  • Second primary cancers in patients with oral cavity cancer included in the Korea Central Cancer Registry
    Seung-Ki Min, Sung Weon Choi, Jiwon Lim, Joo Yong Park, Kyu-Won Jung, Young-Joo Won
    Oral Oncology.2019; 95: 16.     CrossRef
  • Post–Modern Epidemiology: When Methods Meet Matter
    George Davey Smith
    American Journal of Epidemiology.2019; 188(8): 1410.     CrossRef
  • Prognosis of the Metachronous and Synchronous Bilateral Renal Cancer and Second Primary Cancer After the Bilateral Renal Cancer: a Population-Based Analysis
    Mierxiati Abudurexiti, Jun Wang, Ning Shao, Fang-Ning Wan, Wen-Kai Zhu, Bo Dai, Yao Zhu, Ding-Wei Ye
    SN Comprehensive Clinical Medicine.2019; 1(11): 900.     CrossRef
  • Risk of second primary Cancer among bladder Cancer patients: a population-based cohort study in Korea
    Whi-An Kwon, Jae Young Joung, Jiwon Lim, Chang-Mo Oh, Kyu-Won Jung, Sung Han Kim, Ho Kyung Seo, Weon Seo Park, Jinsoo Chung, Kang Hyun Lee, Young-Joo Won
    BMC Cancer.2018;[Epub]     CrossRef
  • 11,565 View
  • 267 Download
  • 18 Web of Science
  • 18 Crossref
Close layer
Current Trends in the Incidence and Survival Rate of Urological Cancers in Korea
Jae Young Joung, Jiwon Lim, Chang-Mo Oh, Kyu-Won Jung, Hyunsoon Cho, Sung Han Kim, Ho Kyung Seo, Weon Seo Park, Jinsoo Chung, Kang Hyun Lee, Young-Joo Won
Cancer Res Treat. 2017;49(3):607-615.   Published online September 23, 2016
DOI: https://doi.org/10.4143/crt.2016.139
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This descriptive study assessed the current trends in the incidence of urological cancers and patient survival in Korea.
Materials and Methods
In this nationwide retrospective observational study based on the data from the Korea National Cancer Incidence Database (KNCIDB), this study analyzed the age-standardized incidence rates (ASRs) and annual percentage changes (APCs) of kidney, bladder, prostate, testicular, and penile cancers as well as cancer of the renal pelvis and ureter between 1999 and 2012. The relative survival rates (RSRs) were calculated for urological cancer patients diagnosed between 1993 and 2012 from the KNCIDB data.
Results
Prostate cancer was diagnosed in 66,812 individuals followed by bladder (41,549) and kidney (36,836) cancers. The overall ASR (18.26 per 100,000) increased with age because of the higher ASRs of bladder and prostate cancers in the elderly. The ASR for kidney cancer was highest in the 40-59-year-old group, whereas testicular cancer occurred most frequently before the age of 40. The incidence of most urological cancers increased (overall APC, 6.39%; p < 0.001), except for penile (APC, –2.01%; p=0.05) and bladder (APC, –0.40%; p=0.25) cancers. The overall survival increased steadily (5-year RSR, 66.4% in 1993-1995 vs. 84.2% in 2008-2012; p < 0.001), particularly for prostate (by 34.10%) and kidney (by 16.30%) cancers, but not for renal pelvis and ureter cancers (–7.20%).
Conclusion
The most common urological cancer in Korea was prostate cancer followed by bladder and kidney cancers. The incidence of most urological cancers, except for penile and bladder cancers, increased. Survival also increased, particularly for prostate and kidney cancers.

Citations

Citations to this article as recorded by  
  • Twenty-two-year incidence trend of urological cancers in the Republic of Korea: 1999–2020
    Seunghyeon Cho, Won-Ju Park
    Investigative and Clinical Urology.2024; 65(1): 23.     CrossRef
  • Risk Factors Associated with Urothelial Bladder Cancer
    Souhail Alouini
    International Journal of Environmental Research and Public Health.2024; 21(7): 954.     CrossRef
  • Optimal sequencing of the first- and second-line target therapies in metastatic renal cell carcinoma: based on nationally representative data analysis from the Korean National Health Insurance System
    Dong Hyuk Kang, Joo Yong Lee, Yunhee Lee, U-Syn Ha
    BMC Cancer.2023;[Epub]     CrossRef
  • Empowerment-Based Education in Urological Patients: A Scoping Review
    Giulia Villa, Emanuele Galli, Vittoria Azzimonti, Marianna Doneda, Noemi Giannetta, Duilio Fiorenzo Manara
    Clinical Nursing Research.2022; 31(4): 666.     CrossRef
  • Incidence and mortality projections for major cancers among Korean men until 2034, with a focus on prostate cancer
    Sahyun Pak, Kyu-Won Jung, Eun-Hye Park, Young Hwii Ko, Young-Joo Won, Jae Young Joung
    Investigative and Clinical Urology.2022; 63(2): 175.     CrossRef
  • MicroRNA Signatures in the Upper Urinary Tract Urothelial Carcinoma Scenario: Ready for the Game Changer?
    Alessandra Cinque, Anna Capasso, Riccardo Vago, Matteo Floris, Michael W. Lee, Roberto Minnei, Francesco Trevisani
    International Journal of Molecular Sciences.2022; 23(5): 2602.     CrossRef
  • Trends of First-Line Targeted Therapy in Korean Patients With Metastatic Clear Cell Renal Cell Carcinoma: Sunitinib Versus Pazopanib, a Multicenter Study
    Minsu Choi, Teak Jun Shin, Byung Hoon Kim, Chun Il Kim, Kyung Seop Lee, Seock Hwan Choi, Hyun Tae Kim, Tae-Hwan Kim, Tae Gyun Kwon, Young Hwii Ko, Yoon Soo Hah, Jae-Shin Park, Se Yun Kwon
    The Korean Journal of Urological Oncology.2022; 20(2): 115.     CrossRef
  • The association between pain intensity and disability in patients with failed back surgery syndrome, treated with spinal cord stimulation
    Mats De Jaeger, Lisa Goudman, Sam Eldabe, Robert Van Dongen, Ann De Smedt, Maarten Moens
    Disability and Rehabilitation.2021; 43(15): 2157.     CrossRef
  • Rapid recurrence of squamous cell carcinoma at a lymphocele after nephroureterectomy: A rare case report
    Kosuke Ogawa, Yousuke Shimizu, Shoko Uketa, Noriaki Utsunomiya, Satsuki Asai, Misa Ishihara, Kimio Hashimoto, Sojun Kanamaru
    IJU Case Reports.2021; 4(2): 118.     CrossRef
  • Survival and Characteristics of Bladder Cancer: Analysis of the Malaysian National Cancer Registry
    Mohd Nasrullah Nik Ab Kadir, Suhaily Mohd Hairon, Najib Majdi Yaacob, Azizah Ab Manan, Nabihah Ali
    International Journal of Environmental Research and Public Health.2021; 18(10): 5237.     CrossRef
  • The incidence and prevalence of upper tract urothelial carcinoma: a systematic review
    Ahmed Soualhi, Elke Rammant, Gincy George, Beth Russell, Deborah Enting, Rajesh Nair, Mieke Van Hemelrijck, Cecilia Bosco
    BMC Urology.2021;[Epub]     CrossRef
  • Impact of chemotherapy on subsequent generations
    Biren V. Patel, James M. Hotaling
    Urologic Oncology: Seminars and Original Investigations.2020; 38(1): 10.     CrossRef
  • Financial toxicity and its associations with health-related quality of life among urologic cancer patients in an upper middle-income country
    Chuo Yew Ting, Guan Chou Teh, Kong Leong Yu, Haridah Alias, Hui Meng Tan, Li Ping Wong
    Supportive Care in Cancer.2020; 28(4): 1703.     CrossRef
  • Time Trends for Prostate Cancer Incidence from 2003 to 2013 in South Korea: An Age-Period-Cohort Analysis
    Hyun Young Lee, Do Kyoung Kim, Seung Whan Doo, Won Jae Yang, Yun Seob Song, Bora Lee, Jae Heon Kim
    Cancer Research and Treatment.2020; 52(1): 301.     CrossRef
  • Anesthetic considerations for urologic surgeries
    Chang-Hoon Koo, Jung-Hee Ryu
    Korean Journal of Anesthesiology.2020; 73(2): 92.     CrossRef
  • Emergency room imaging in patients with genitourinary cancers: analysis of the spectrum of CT findings and their relation to patient outcomes
    Sungmin Woo, Jad Bou Ayache, Peter Sawan, Julian Infantino, Natalie Gangai, Andreas Wibmer, Hedvig Hricak, Jeffrey S. Groeger, Hebert Alberto Vargas
    Emergency Radiology.2020; 27(4): 413.     CrossRef
  • Detection of Incidental Prostate Cancer or Urothelial Carcinoma Extension in Urinary Bladder Cancer Patients by Using Multiparametric MRI: A Retrospective Study Using Prostate Imaging Reporting and Data System Version 2.0
    Sang Eun Yoon, Byung Chul Kang, Hyun-Hae Cho, Sanghui Park
    Journal of the Korean Society of Radiology.2020; 81(3): 610.     CrossRef
  • Health-Related Quality of Life, Perceived Social Support, and Depression in Disease-Free Survivors Who Underwent Curative Surgery Only for Prostate, Kidney and Bladder Cancer: Comparison among Survivors and with the General Population
    Dong Wook Shin, Hyun Sik Park, Sang Hyub Lee, Seung Hyun Jeon, Seok Cho, Seok Ho Kang, Seung Chol Park, Jong Hyock Park, Jinsung Park
    Cancer Research and Treatment.2019; 51(1): 289.     CrossRef
  • Synchronous Bilateral RCC Is Associated With Poor Recurrence-Free Survival Compared With Unilateral RCC: A Single-Center Study With Propensity Score Matching Analysis
    Jung Kwon Kim, Hakmin Lee, Jong Jin Oh, Sangchul Lee, Sung Kyu Hong, Sang Eun Lee, Seok-Soo Byun
    Clinical Genitourinary Cancer.2019; 17(3): e570.     CrossRef
  • Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using th
    Jung Kwon Kim, Sung Han Kim, Mi Kyung Song, Jungnam Joo, Seong Il Seo, Cheol Kwak, Chang Wook Jeong, Cheryn Song, Eu Chang Hwang, Ill Young Seo, Hakmin Lee, Sung-Hoo Hong, Jae Young Park, Jinsoo Chung
    Cancer Research and Treatment.2019; 51(2): 758.     CrossRef
  • Trends in clinical, operative, and pathologic characteristics of surgically treated renal mass in a Korean center: A surgical series from 1988 through 2015
    Ho Won Kang, Sung Pil Seo, Won Tae Kim, Seok Joong Yun, Sang-Cheol Lee, Wun-Jae Kim, Eu Chang Hwang, Seok Ho Kang, Sung-Hoo Hong, Jinsoo Chung, Tae Gyun Kwon, Hyeon Hoe Kim, Cheol Kwak, Seok-Soo Byun, Yong-June Kim
    Investigative and Clinical Urology.2019; 60(3): 184.     CrossRef
  • Survival and clinical prognostic factors in metastatic non‐clear cell renal cell carcinoma treated with targeted therapy: A multi‐institutional, retrospective study using the Korean metastatic renal cell carcinoma registry
    Jung Kwon Kim, Sung Han Kim, Mi Kyung Song, Jungnam Joo, Seong Il Seo, Cheol Kwak, Chang Wook Jeong, Cheryn Song, Eu Chang Hwang, Ill Young Seo, Hakmin Lee, Sung‐Hoo Hong, Jae Young Park, Jinsoo Chung
    Cancer Medicine.2019; 8(7): 3401.     CrossRef
  • The Prognostic Significance of Protein Expression of CASZ1 in Clear Cell Renal Cell Carcinoma
    Bohyun Kim, Minsun Jung, Kyung Chul Moon
    Disease Markers.2019; 2019: 1.     CrossRef
  • History of Diabetes Mellitus and Risk of Prostate Cancer: A Meta-Epidemiological Study of Population-Based Cohort Studies in East Asian Men
    Jong-Myon Bae
    The Korean Journal of Urological Oncology.2019; 17(3): 119.     CrossRef
  • Development and Validation of the Korean Version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients with Non-muscle Invasive Bladder Cancer: EORTC QLQ-NMIBC24
    Jinsung Park, Dong Wook Shin, Tae-Hwan Kim, Seung Il Jung, Jong Kil Nam, Seung Chol Park, Sungwoo Hong, Jae Hung Jung, Hongwook Kim, Won Tae Kim
    Cancer Research and Treatment.2018; 50(1): 40.     CrossRef
  • Rate and association of lower urinary tract infection with recurrence after transurethral resection of bladder tumor
    Byung Soo Kim, Bum Sik Tae, Ja Hyeon Ku, Cheol Kwak, Hyeon Hoe Kim, Chang Wook Jeong
    Investigative and Clinical Urology.2018; 59(1): 10.     CrossRef
  • Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy
    Seung Bin Kim, Sung Goo Yoon, Jonghyun Tae, Jae Yoon Kim, Ji Sung Shim, Sung Gu Kang, Jun Cheon, Jeong Gu Lee, Je Jong Kim, Seok Ho Kang
    Investigative and Clinical Urology.2018; 59(2): 98.     CrossRef
  • Significance of Intratumoral Fibrosis in Clear Cell Renal Cell Carcinoma
    Jae Won Joung, Hoon Kyu Oh, Sun Jae Lee, Young Ah Kim, Hyun Jin Jung
    Journal of Pathology and Translational Medicine.2018; 52(5): 323.     CrossRef
  • Yes-Associated Protein Expression Is Correlated to the Differentiation of Prostate Adenocarcinoma
    Myung-Giun Noh, Sung Sun Kim, Eu Chang Hwang, Dong Deuk Kwon, Chan Choi
    Journal of Pathology and Translational Medicine.2017; 51(4): 365.     CrossRef
  • 12,671 View
  • 264 Download
  • 24 Web of Science
  • 29 Crossref
Close layer
Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy
Sung Han Kim, Weon Seo Park, Sun Ho Kim, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
Cancer Res Treat. 2016;48(3):1092-1101.   Published online January 28, 2016
DOI: https://doi.org/10.4143/crt.2015.316
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to compare the outcomes of first-line systemic targeted therapy (TT) and immunotherapy (IT) in patients with metastatic renal cell carcinoma (mRCC).
Materials and Methods
This study was a retrospective review of the data of 262 patients treated with systemic IT or TT with tyrosine kinase inhibitors between 2003 and 2013. The objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were assessed using Response Evaluation Criteria in Solid Tumor ver. 1.0 criteria and the Kaplan-Meier method with log-rank test.
Results
During the median 4.3-month treatment and the 24-month follow-up period, the ORR/PFS/OS of the overall first-line and second-line therapy were 41.9%/8.1 months/16.8 months and 27.5%/6.5 months/15.3 months, respectively. The first-line TT/IT/sequential IT had a PFS of 9.3/6.4/5.7 months and an OS of 15.8/16.5/40.6 months (all p < 0.05). The second-line of TT/IT had a PFS of 7.1/2.1 months (both p < 0.05) and an OS of 16.6/8.6 months (p=0.636), respectively. Pazopanib provided the best median PFS of 11.0 months (p < 0.001) and a quadruple IT regimen had a superior PFS (p=0.522). For OS, sequential treatment with IT and TT was superior compared to treatment with either IT or TT alone (40.6/16.5/15.8 months, p=0.014). The prognosis according to the Memorial Sloan Kettering Cancer Center model showed that favorable/intermediate/poor risk groups had a PFS of 8.5/10.4/2.3 months, and an OS of 43.1/20.4/5.6 months, respectively. The prognosis calculated using the Heng model showed that the favorable/intermediate/poor risk groups had a PFS of 9.2/3.9/2.7 months, and an OS of 32.4/16.5/6.1months, respectively (all p < 0.001).
Conclusion
In patients with mRCC, TT provided a better PFS and OS compared with IT.

Citations

Citations to this article as recorded by  
  • Optimal sequencing of the first- and second-line target therapies in metastatic renal cell carcinoma: based on nationally representative data analysis from the Korean National Health Insurance System
    Dong Hyuk Kang, Joo Yong Lee, Yunhee Lee, U-Syn Ha
    BMC Cancer.2023;[Epub]     CrossRef
  • Adenovirus vaccine therapy with CD137L promotes CD8+ DCs-mediated multifunctional CD8+ T cell immunity and elicits potent anti-tumor activity
    Jiage Ding, Nan Jiang, Yanyan Zheng, Jiawei Wang, Lin Fang, Huizhong Li, Jie Yang, Ankang Hu, Pengli Xiao, Qing Zhang, Dafei Chai, Junnian Zheng, Gang Wang
    Pharmacological Research.2022; 175: 106034.     CrossRef
  • Skeletal Muscle Metastasis From Renal Cell Carcinoma: A Case Series and Literature Review
    Juan Sun, Zimu Zhang, Yu Xiao, Hanzhong Li, Zhigang Ji, Penghu Lian, Xuebin Zhang
    Frontiers in Surgery.2022;[Epub]     CrossRef
  • Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry
    Margaret F. Meagher, Maria C Mir, Riccardo Autorino, Andrea Minervini, Maximilian Kriegmair, Tobias Maurer, Francesco Porpiglia, Siska Van Bruwaene, Estefania Linares, Vital Hevia, Mireia Musquera, Eduard Roussel, Nicola Pavan, Alessandro Antonelli, Shudo
    Clinical Genitourinary Cancer.2022; 20(4): 326.     CrossRef
  • Comparison of prognostic factors that affect the survival of patients with metachronous and synchronous metastases of renal cell carcinoma
    D. V. Semenov, R. V. Orlova, V. I. Shirokorad, S. V. Kostritsky, S. G. Grigoriev, Yu. S. Korneva
    Urology Herald.2022; 10(3): 65.     CrossRef
  • Co‐immunization with L‐Myc enhances CD8+ or CD103+ DCs mediated tumor‐specific multi‐functional CD8+ T cell responses
    Dafei Chai, Zichun Zhang, Nan Jiang, Jiage Ding, Dong Qiu, Shang Yuchen Shi, Gang Wang, Lin Fang, Huizhong Li, Hui Tian, Jie Yang, Qing Zhang, Junnian Zheng
    Cancer Science.2021; 112(9): 3469.     CrossRef
  • Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study
    Sung Han Kim, Dong-Eun Lee, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
    Investigative and Clinical Urology.2020; 61(2): 146.     CrossRef
  • Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself
    Qian-Kun Yang, Tong Chen, Shi-Qi Wang, Xiao-Jing Zhang, Zhong-Xiang Yao
    Angiogenesis.2020; 23(3): 279.     CrossRef
  • Surgical-only treatment of pancreatic and extra-pancreatic metastases from renal cell carcinoma - quality of life and survival analysis
    Stefania Brozzetti, Simone Bini, Nelide De Lio, Carlo Lombardo, Ugo Boggi
    BMC Surgery.2020;[Epub]     CrossRef
  • Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy
    Sung Han Kim, Jung Kwon Kim, Eun Young Park, Jungnam Joo, Kang Hyun Lee, Ho Kyung Seo, Jae Young Joung, Jinsoo Chung, Aamir Ahmad
    PLOS ONE.2019; 14(2): e0211105.     CrossRef
  • A Retrospective Analysis of the Impact of Metastasectomy on Prognostic Survival According to Metastatic Organs in Patients With Metastatic Renal Cell Carcinoma
    Sung Han Kim, Weon Seo Park, Boram Park, Sahyun Pak, Jinsoo Chung
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis
    Sung Han Kim, Dong-eun Lee, Boram Park, Jungnam Joo, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
    BMC Cancer.2019;[Epub]     CrossRef
  • Prognostic significance of nephrectomy in metastatic renal cell carcinoma treated with systemic cytokine or targeted therapy: A 16-year retrospective analysis
    Sung Han Kim, Kyung-Chae Jeong, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
    Scientific Reports.2018;[Epub]     CrossRef
  • The effect of a gene associated with retinoid-interferon-induced mortality 19 (GRIM-19) on STAT3-induced gene expression in renal carcinoma
    Lingang Cui, Qingjun Meng, Jianguo Wen, Zechen Yan, Zhan Gao, Yudong Tian, Pengchao Xu, Pengchao Lian, Haizhou Yu
    The Journal of Biochemistry.2018; 164(4): 285.     CrossRef
  • The Experience of Uncertainty in Cancer Patients Undergoing Chemotherapy
    Yoon Sun Kim, Young Sook Tae, Keum Hee Nam, Heui Yeoung Kim
    Asian Oncology Nursing.2018; 18(3): 115.     CrossRef
  • Suppression of homology-dependent DNA double-strand break repair induces PARP inhibitor sensitivity inVHL-deficient human renal cell carcinoma
    Susan E. Scanlon, Denise C. Hegan, Parker L. Sulkowski, Peter M. Glazer
    Oncotarget.2018; 9(4): 4647.     CrossRef
  • Uncharacteristic metastasis of a renal clear-cell carcinoma to the muscles of the forearm—case report
    Oliwia Kozak, Paweł Turzyński, Karolina Markiet, Joanna Pieńkowska, Katarzyna Skrobisz-Balandowska, Michał Studniarek
    BJR|case reports.2017; 3(3): 20150495.     CrossRef
  • LncRNA RP11-436H11.5, functioning as a competitive endogenous RNA, upregulates BCL-W expression by sponging miR-335-5p and promotes proliferation and invasion in renal cell carcinoma
    Kefeng Wang, Wei Jin, Yan Song, Xiang Fei
    Molecular Cancer.2017;[Epub]     CrossRef
  • Anti-angiogenesis target therapy for advanced osteosarcoma
    Lu Xie, Tao Ji, Wei Guo
    Oncology Reports.2017; 38(2): 625.     CrossRef
  • A retrospective comparative study of progression-free survival and overall survival between metachronous and synchronous metastatic renal cell carcinoma in intermediate- or poor-risk patients treated with VEGF-targeted therapy
    Sung Han Kim, Yoon Seok Suh, Dong-Eun Lee, Boram Park, Jungnam Joo, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
    Oncotarget.2017; 8(55): 93633.     CrossRef
  • Survival outcomes of double- and triple-sequential targeted therapy in patients with metastatic renal cell carcinoma: a retrospective comparison
    Sung Han Kim, Yoon Seok Suh, Jung Kwon Kim, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
    Oncotarget.2017; 8(59): 100056.     CrossRef
  • Introducing, OncoTarget
    Mikhail Blagosklonny, Andrei Gudkov
    Oncotarget.2010; 1(1): 2.     CrossRef
  • Introducing, OncoTarget
    Mikhail Blagosklonny, Andrei Gudkov
    Oncotarget.2010; 1(1): 2.     CrossRef
  • 11,864 View
  • 171 Download
  • 22 Web of Science
  • 23 Crossref
Close layer
Case Report
A Case Report of Partial Nephrectomy of Mucinous Cystadenocarcinoma in Kidney and Its Literature Review
Sung Han Kim, Heong Dong Yuk, Weon Seo Park, Sun Ho Kim, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
Cancer Res Treat. 2016;48(2):838-842.   Published online February 13, 2015
DOI: https://doi.org/10.4143/crt.2014.219
AbstractAbstract PDFPubReaderePub
Mucinous cystadenocarcinoma (MC) of the kidney is a rare epithelial tumor originating from the renal pelvic urothelium and few study cases have been reported. Because of the rarity of these tumors and their unknown histogenesis, its diagnosis is difficult until surgical exploration. We report here on a 55-year-old man referred to the urology department from the hepatology department because of a cystic renal mass measuring approximately 5 cm in size, which was detected incidentally under ultrasonography during the routine examination of liver. The renal mass was finally diagnosed as MC originating from kidney after partial nephrectomy and the patient still showed no evidence of recurrence until 12 months postoperatively. This is the first report on a case of renal MC in a patient who underwent partial nephrectomy. The aim of this report is to present our unusual case of MC and also review the previous literature on the pathological and radiological aspects of MC of kidney.

Citations

Citations to this article as recorded by  
  • Mucinous adenocarcinoma in kidneys with developmental anomalies - a report of two cases
    Kasi Viswanath Gali, Arun Chawla, K. R. Surag, Sunil Pillai Bhaskara, Padmaraj Hegde
    BMC Urology.2024;[Epub]     CrossRef
  • Case report and literature review: Robot-assisted laparoscopic left renal mucinous cystadenocarcinoma radical nephrectomy
    Zikuan Ning, Haoxun Zhang, Bowen Wang, Yingwei Wang, Yiwen Liu, Boju Tao, Guoling Zhang, Hua Liu, Chunyang Wang
    Frontiers in Surgery.2023;[Epub]     CrossRef
  • Mucinous cystadenocarcinoma in the renal pelvis: primary or secondary? Case report and literature review
    An Tamsin, Charlotte Schillebeeckx, Charlotte Van Langenhove, Kathy Vander Eeckt, Dieter Ost, Kevin Wetzels
    Acta Chirurgica Belgica.2020; 120(6): 417.     CrossRef
  • 24,089 View
  • 119 Download
  • 6 Web of Science
  • 3 Crossref
Close layer
Original Article
Bcl-2 as a Predictive Factor for Biochemical Recurrence after Radical Prostatectomy: An Interim Analysis
In-Chang Cho, Han Soo Chung, Kang Su Cho, Jeong Eun Kim, Jae Young Joung, Ho Kyung Seo, Jinsoo Chung, Weon Seo Park, Eun Kyung Hong, Kang Hyun Lee
Cancer Res Treat. 2010;42(3):157-162.   Published online September 30, 2010
DOI: https://doi.org/10.4143/crt.2010.42.3.157
AbstractAbstract PDFPubReaderePub
Purpose

The objective of this study was to determine Bcl-2 expression in localized prostate cancer and its potential role as a predictive factor for biochemical recurrence (BCR).

Materials and Methods

This study included 171 Korean patients with newly diagnosed adenocarcinoma of the prostate who underwent radical prostatectomy (RP) without neoadjuvant therapy at a single center between February 2005 and May 2009. RP specimens obtained from these patients were analyzed for the expression of Bcl-2 using tissue microarray. The values of Bcl-2 and other clinicopathologic factors were evaluated. Statistical analysis was performed with contingency table analysis, chi-square tests, and a Cox proportional hazard model.

Results

Bcl-2 expression was immunohistologically-confirmed in 42 patients (24.6%). Bcl-2 expression was not associated with conventional clinicopathologic factors. Bcl-2 negative patients had a significantly longer mean BCR-free survival than Bcl-2-positive patients (p=0.036). Among several variables, a high Gleason score in the RP specimen (≥8), extraprostatic extension, seminal vesicle invasion (SVI), lymphovascular invasion (LVI), and Bcl-2 expression were significant predictors of BCR based on univariate analysis. Multivariate Cox proportional hazards analysis revealed that BCR was significantly associated with a high prostate specific antigen level (p=0.047), SVI (p<0.001), a positive surgical margin (p=0.004) and Bcl-2 expression (p=0.012).

Conclusion

Bcl-2 expression in RP specimens is associated with a significantly worse outcome, suggesting a potential clinical role for Bcl-2. Post-operative Bcl-2 could be a significant predictor of outcome after RP.

Citations

Citations to this article as recorded by  
  • Association of Lymphovascular Invasion with Biochemical Recurrence and Adverse Pathological Characteristics of Prostate Cancer: A Systematic Review and Meta-analysis
    Jakub Karwacki, Marcel Stodolak, Andrzej Dłubak, Łukasz Nowak, Adam Gurwin, Kamil Kowalczyk, Paweł Kiełb, Nazar Holdun, Wojciech Szlasa, Wojciech Krajewski, Agnieszka Hałoń, Anna Karwacka, Tomasz Szydełko, Bartosz Małkiewicz
    European Urology Open Science.2024; 69: 112.     CrossRef
  • Immunohistochemical Expression of MDM2, Bcl-2, SATB2 and Ki-67 in Histological Variants of Unicystic Ameloblastoma
    Koustubh Amol Surana, Deepak Pandiar, Reshma Poothakulath Krishnan
    Head and Neck Pathology.2024;[Epub]     CrossRef
  • Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer
    Daniel Westaby, Juan M. Jimenez-Vacas, Ana Padilha, Andreas Varkaris, Steven P. Balk, Johann S. de Bono, Adam Sharp
    Cancers.2021; 14(1): 51.     CrossRef
  • miR-205: A Potential Biomedicine for Cancer Therapy
    Neeraj Chauhan, Anupam Dhasmana, Meena Jaggi, Subhash C. Chauhan, Murali M. Yallapu
    Cells.2020; 9(9): 1957.     CrossRef
  • Bcl‐2 is a prognostic marker and its silencing inhibits recurrence in ameloblastomas
    Jue Young Kim, Jinsun Kim, Shadavlonjid Bazarsad, In‐Ho Cha, Sung‐Won Cho, Jin Kim
    Oral Diseases.2019; 25(4): 1158.     CrossRef
  • Tumor-Specific Induction of the Intrinsic Apoptotic Pathway—A New Therapeutic Option for Advanced Prostate Cancer?
    Philipp Wolf
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • PI3K pathway and Bcl-2 family. Clinicopathological features in prostate cancer
    Norelia Torrealba, Gonzalo Rodriguez-Berriguete, Benito Fraile, Gabriel Olmedilla, Pilar Martínez-Onsurbe, Manuel Sánchez-Chapado, Ricardo Paniagua, Mar Royuela
    The Aging Male.2018; 21(3): 211.     CrossRef
  • Positive surgical margin is associated with biochemical recurrence risk following radical prostatectomy: a meta-analysis from high-quality retrospective cohort studies
    Lijin Zhang, Bin Wu, Zhenlei Zha, Hu Zhao, Yuefang Jiang, Jun Yuan
    World Journal of Surgical Oncology.2018;[Epub]     CrossRef
  • The impact of lymphovascular invasion in patients with prostate cancer following radical prostatectomy and its association with their clinicopathological features
    Wei Jiang, Lijin Zhang, Bin Wu, Zhenlei Zha, Hu Zhao, Yuan Jun, Yuefang Jiang
    Medicine.2018; 97(49): e13537.     CrossRef
  • Bcl2 en cáncer avanzado de próstata y asociación con resistencia a la castración
    R.F. Velázquez-Macías, F.E. De La Torre-Rendón, G. Ramos-Rodríguez, C.A. Calzada-Mendoza, R.M. Coral-Vázquez
    Revista Mexicana de Urología.2016; 76(5): 288.     CrossRef
  • Application of a new technique, spiral tissue microarrays constructed using needle biopsy specimens, to prostate cancer research
    AKIRA KOMIYA, TOMONORI KATO, TAKASHI HORI, JUNYA FUKUOKA, KENJI YASUDA, HIDEKI FUSE
    International Journal of Oncology.2014; 44(1): 195.     CrossRef
  • MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer
    BERLINDA VERDOODT, MATTHIAS NEID, MARKUS VOGT, VIKTORIA KUHN, SVEN-THORSTEN LIFFERS, REIN-JÜRI PALISAAR, JOACHIM NOLDUS, ANDREA TANNAPFEL, ALIREZA MIRMOHAMMADSADEGH
    International Journal of Oncology.2013; 43(1): 307.     CrossRef
  • 9,200 View
  • 61 Download
  • 12 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP